PCR Journal Club

In this prespecified subgroup analysis of the AFIRE trial, the authors report the outcomes of rivaroxaban monotherapy compared to rivaroxaban and an antiplatelet agent in patients with atrial fibrillation who underwent coronary stenting > 1 year prior to enrolment.

The FUTURE Trial is a prospective randomised, multicentre, open label superiority trial comparing an FFR guided treatment strategy to traditional angiography guided treatment strategy on clinical outcomes in an all-comer population with multivessel coronary artery disease.

To further investigate the treatment effects of ticagrelor monotherapy compared with ticagrelor plus aspirin in a contemporary HBR population, a pre-specified analysis of the TWILIGHT trial, TWILIGHT-HBR, was conducted by using the Academic Research Consortium (ARC) criteria for HBR.

According to the updated international revascularization guidelines, fractional flow reserve (FFR) and instantaneous wave-free period ratio (iFR) are proposed to dichotomize decision-making for ischemia detection in guiding percutaneous coronary intervention (PCI) of intermediate coronary stenosis.

The objective of the IAMI1 trial was to determine whether early influenza vaccination reduces the risk of cardiovascular events in patients admitted with an acute-MI or high-risk stable coronary artery disease in an adequately powered randomized control trial setting.

The aim of this study was to understand the impact of optical coherence tomography (OCT)-detected thin-cap fibroatheroma (TCFA) on clinical outcomes of diabetes mellitus (DM) patients with fractional flow reserve (FFR)-negative lesions.

This analysis highlights that, in appropriate hands, ISR CTO-PCI is safe, with similar success rates to de-novo CTO-PCI.

Find out more about the results of this analysis which suggest that operator experience may be an important effect modifier in ROTA-PCI.

The HOST-EXAM trial sought to define whether, after DAPT for PCI with DES, clopidogrel monotherapy is associated with improved outcomes compared with aspirin monotherapy.

This study aimed to delineate the external validity of the ISCHEMIA trial by applying the ISCHEMIA inclusion and exclusion criteria to an established cohort of patients with stable coronary disease in an observational setting.